hydroxyindoleacetic acid has been researched along with Parkinson Disease, Secondary in 36 studies
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 7.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a syndrome that resembles Parkinson's disease." | 3.67 | The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Burns, RS; Ebert, MH; Kopin, IJ; LeWitt, PA; Pakkenberg, H, 1985) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "Prodipin does not cause an alteration in metabolite concentration in cases of interrupted therapy (group 1), but leads, in the case of continued therapy, to a 1." | 2.64 | CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application. ( Oppel, F; Schulze, G, 1978) |
| "We describe two sporadic cases of dystonia-parkinsonism at different stages of disease progression." | 1.28 | Consideration on two cases of dystonia-parkinsonism. ( Balottin, U; Borgatti, R; Lanzi, G; Zambrino, CA, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (50.00) | 18.7374 |
| 1990's | 13 (36.11) | 18.2507 |
| 2000's | 3 (8.33) | 29.6817 |
| 2010's | 2 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Herbert, MK | 1 |
| Kuiperij, H | 1 |
| Bloem, BR | 1 |
| Verbeek, MM | 1 |
| Navailles, S | 1 |
| Benazzouz, A | 1 |
| Bioulac, B | 1 |
| Gross, C | 1 |
| De Deurwaerdère, P | 1 |
| Taylor, JL | 1 |
| Bishop, C | 1 |
| Walker, PD | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Falaschi, P | 1 |
| Baldassarre, M | 1 |
| D'Urso, R | 1 |
| Forchetti, C | 1 |
| Polleri, A | 1 |
| Vanderheyden, JE | 1 |
| Dekoninck, WJ | 1 |
| Lefèvre, A | 1 |
| Mendlewicz, J | 1 |
| Fornaguera, J | 1 |
| Schwarting, RK | 1 |
| Boix, F | 1 |
| Huston, JP | 1 |
| Wesemann, W | 1 |
| Grote, C | 1 |
| Clement, HW | 1 |
| Block, F | 1 |
| Sontag, KH | 1 |
| Altagracia, M | 1 |
| Rojas, P | 1 |
| Kravzov, J | 1 |
| Rios, C | 1 |
| Matsubara, K | 1 |
| Gonda, T | 1 |
| Sawada, H | 1 |
| Uezono, T | 1 |
| Kobayashi, Y | 1 |
| Kawamura, T | 1 |
| Ohtaki, K | 1 |
| Kimura, K | 1 |
| Akaike, A | 1 |
| Di Rocco, A | 1 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Yahr, MD | 1 |
| Cheng, FC | 1 |
| Ni, DR | 1 |
| Wu, MC | 1 |
| Kuo, JS | 1 |
| Chia, LG | 1 |
| Dethy, S | 1 |
| Laute, MA | 1 |
| Damhaut, P | 1 |
| Goldman, S | 1 |
| Ueda, S | 1 |
| Aikawa, M | 1 |
| Ishizuya-Oka, A | 1 |
| Yamaoka, S | 1 |
| Koibuchi, N | 1 |
| Yoshimoto, K | 1 |
| Abe, K | 1 |
| Taguchi, K | 1 |
| Wasai, T | 1 |
| Ren, J | 1 |
| Utsunomiya, I | 1 |
| Shinohara, T | 1 |
| Miyatake, T | 1 |
| Sano, T | 1 |
| Oppel, F | 1 |
| Schulze, G | 1 |
| Rüther, E | 2 |
| Schilkrut, R | 2 |
| Ackenheil, M | 2 |
| Eben, E | 2 |
| Hippius, H | 2 |
| Gerlach, J | 1 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Doudet, DJ | 1 |
| Aigner, TG | 1 |
| McLellan, CA | 1 |
| Cohen, RM | 1 |
| García Ruiz, PJ | 1 |
| Mena, MA | 1 |
| Peñafiel, N | 1 |
| De Yébenes, JG | 1 |
| Skirboll, S | 1 |
| Wang, J | 1 |
| Mefford, I | 1 |
| Hsiao, J | 1 |
| Bankiewicz, KS | 1 |
| Pezzoli, G | 1 |
| Ricciardi, S | 1 |
| Masotto, C | 1 |
| Mariani, CB | 1 |
| Carenzi, A | 1 |
| Rausch, WD | 1 |
| Schallauer, E | 1 |
| Chan, WW | 1 |
| Riederer, P | 1 |
| Weiser, M | 1 |
| Zambrino, CA | 1 |
| Balottin, U | 1 |
| Borgatti, R | 1 |
| Lanzi, G | 1 |
| Bradbury, AJ | 1 |
| Costall, B | 1 |
| Jenner, PG | 1 |
| Kelly, ME | 1 |
| Marsden, CD | 1 |
| Naylor, RJ | 1 |
| Kish, SJ | 1 |
| Chang, LJ | 1 |
| Mirchandani, L | 1 |
| Shannak, K | 1 |
| Hornykiewicz, O | 1 |
| Di Paolo, T | 1 |
| Bédard, P | 1 |
| Daigle, M | 1 |
| Boucher, R | 1 |
| Saito, T | 1 |
| Ishizawa, H | 1 |
| Tsuchiya, F | 1 |
| Ozawa, H | 1 |
| Takahata, N | 1 |
| Johannessen, JN | 1 |
| Savitt, JM | 1 |
| Markey, CJ | 1 |
| Bacon, JP | 1 |
| Weisz, A | 1 |
| Hanselman, DS | 1 |
| Markey, SP | 1 |
| Yamamoto, M | 1 |
| Ujike, H | 1 |
| Ogawa, N | 1 |
| Teelken, AW | 1 |
| van den Berg, GA | 1 |
| Muskiet, FA | 1 |
| Staal-Schreinemachers, AL | 1 |
| Wolthers, BG | 1 |
| Lakke, JP | 1 |
| Burns, RS | 1 |
| LeWitt, PA | 1 |
| Ebert, MH | 1 |
| Pakkenberg, H | 1 |
| Kopin, IJ | 1 |
| Russ, H | 1 |
| Henning, K | 1 |
| Eckhardt, H | 1 |
| Przuntek, H | 1 |
| Collins, MA | 1 |
| Neafsey, EJ | 1 |
| Portmann-Cristesco, EM | 1 |
| Boissier, JR | 1 |
| Chase, TN | 1 |
2 reviews available for hydroxyindoleacetic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[Use of the probenecid test for the diagnosis and treatment of Parkinsonism. Review of the literature and personal experience (author's transl)].
Topics: Aged; Brain; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Middle Aged; Neu | 1980 |
Serotonergic mechanisms and extrapyramidal function in man.
Topics: 5-Hydroxytryptophan; Carbidopa; Cerebellar Diseases; Creutzfeldt-Jakob Syndrome; Down Syndrome; Extr | 1974 |
2 trials available for hydroxyindoleacetic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
CSF-changes of HVA and 5-HIAA during intermittent and continuous Parkinson therapy with particular regard to prodipin application.
Topics: Aged; Antiparkinson Agents; Clinical Trials as Topic; Female; Homovanillic Acid; Humans; Hydroxyindo | 1978 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
32 other studies available for hydroxyindoleacetic acid and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.
Topics: Aged; Cerebrovascular Disorders; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 2013 |
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Combined Modality Therapy; Deep Brain Stimulation; Extracellular Spac | 2010 |
Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Benzazepines; Corpu | 2005 |
A neuropharmacological and neuroendocrine study on idiopathic and chronic pharmacological Parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Circadian Rhythm; Homovanillic Acid; Humans; Hyd | 1980 |
Behavioral indices of moderate nigro-striatal 6-hydroxydopamine lesion: a preclinical Parkinson's model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Functi | 1993 |
Functional studies on monoaminergic transmitter release in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; A | 1993 |
Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Brain Chemistry; Corpus Striatum; | 1993 |
Endogenously occurring beta-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Monoamines; Brain; Carbolines; Cells, Cultured; Do | 1998 |
Sertraline induced parkinsonism. A case report and an in-vivo study of the effect of sertraline on dopamine metabolism.
Topics: 1-Naphthylamine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Antidepressive Agents, Second-Genera | 1998 |
Glial cell line-derived neurotrophic factor protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in C57BL/6 mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; | 1998 |
Pergolide potentiates L-DOPA-induced dopamine release in rat striatum after lesioning with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Ago | 1999 |
Age-related dopamine deficiency in the mesostriatal dopamine system of zitter mutant rats: regional fiber vulnerability in the striatum and the olfactory tubercle.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Antibodies; Disease Models, Animal; Dopamine; Free R | 2000 |
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru | 2001 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
Topics: Adult; Aged; Brain Damage, Chronic; Depression; Female; Hallucinations; Haloperidol; Homovanillic Ac | 1976 |
Positron emission tomography with 18F-dopa: interpretation and biological correlates in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carbidopa; Cerebral Cortex; Corpus Striatum; | 1992 |
Cinnarizine-induced parkinsonism in primates.
Topics: Animals; Biogenic Monoamines; Cinnarizine; Disease Models, Animal; Dopamine; Haplorhini; Homovanilli | 1992 |
In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamine | 1990 |
n-hexane induces parkinsonism in rodents.
Topics: Animals; Corpus Striatum; Dopamine; Hexanes; Hexanones; Homovanillic Acid; Hydroxyindoleacetic Acid; | 1990 |
Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amantadine; Animals; C | 1990 |
Consideration on two cases of dystonia-parkinsonism.
Topics: Carbidopa; Child; Dystonia; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; M | 1991 |
The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Female; Homov | 1985 |
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers.
Topics: Aged; Aspartic Acid; Basal Ganglia Diseases; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltrans | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin | 1986 |
Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Epinephrine; | 1986 |
The development of amine substituted analogues of MPTP as unique tools for the study of MPTP toxicity and Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Amines; Animals; Brain | 1987 |
Metoclopramide-induced parkinsonism.
Topics: Aged; Aged, 80 and over; Anorexia; Gastritis; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 1987 |
Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Dopamine; Droxidopa; Female; Homovanillic Acid | 1989 |
The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Corpus Striatum; Dopamine; Female; Homovanillic | 1985 |
The influence of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the levels of dopamine, serotonin and their metabolites in the caudate nucleus of the rat.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucle | 1985 |
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg | 1985 |
[Dopamine release in the rat nigrostratum system after hydroxy-5 tryptophan administration].
Topics: 5-Hydroxytryptophan; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Humans; Hydroxyindoleaceti | 1974 |